In this study, we measured the serum level of full-length CTGF using an antibody against module 4 of CTGF to test the validity of measuring the levels of two types of CTGF (full-length CTGF and N-terminal fragment) to estimate the biopsy-confirmed liver fibrosis stage in patients with FALD and NAFLD. This evidence concerns the gene CCN2 and metabolic dysfunction-associated steatotic liver disease.